FRNMHealthcare · Diagnostics & ResearchTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Freenome, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (85): The share price has been relatively steady.
Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Freenome, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on FRNM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 7% of US stocks
Cheaper than 50% of US stocks
Cheaper than 84% of US stocks
Higher than 99% of US stocks
Higher than 5% of US stocks
Higher than 99% of US stocks
Higher than 78% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FRNM appears on the weeks it earns a place.
The FDA approved Freenome's blood-based colorectal cancer screening test for older adults, with partner Abbott set to launch it in the U.S. this fall.
Why it matters — This FDA approval marks a key regulatory milestone for Freenome's lead product, enabling commercial launch through its partnership with Abbott.
The FDA approved Freenome's SimpleScreen CRC blood-based colorectal cancer screening test, and Abbott will commercialize it in the United States. Medicare coverage and American Cancer Society guidance support broader access to the test, which aims to expand screening options for millions of Americans overdue for screening.
Why it matters — This FDA approval and commercialization partnership with Abbott mark a major regulatory and strategic milestone for Freenome's lead product candidate.
As at 1 Aug 2026, Freenome, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (85 of 100).
No analyst covering Freenome, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FRNM are extrapolating price history, which says nothing about the business.
Freenome, Inc. returned +4.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Freenome, Inc. is a biotechnology company specializing in blood-based early cancer detection.
The most recent item we track (Reuters, 27 July 2026): "FDA approves Freenome's blood test for colorectal cancer screening". The FDA approved Freenome's blood-based colorectal cancer screening test for older adults, with partner Abbott set to launch it in the U.S. this fall.
Freenome, Inc. is a biotechnology company specializing in blood-based early cancer detection. Using a comprehensive multiomics platform that integrates molecular biology, computational biology, and machine learning, Freenome develops noninvasive screening tests based on a routine blood draw. Its technology analyzes a wide range of circulating biomarkers, including cell-free DNA, RNA, proteins, and immune-related signals, to identify cancer at its earliest, most treatable stages. Freenome focuses on next-generation diagnostics for cancers such as colorectal and other solid tumors, serving healthcare providers, health systems, and population health decision-makers with tools designed to improve cancer screening and precision oncology workflows. The company also engages in clinical research programs to support development, discovery, and validation of single-cancer and multi-cancer tests. Founded in 2014 and headquartered in Brisbane, California, Freenome plays a notable role in the life sciences and healthcare sectors as a provider of advanced cancer detection solutions powered by AI-driven genomics and multiomics analysis.
CEO Mr. Aaron Elliott Ph.D. · 363 employees · United States · https://www.freenome.com